Basal Cell Carcinoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Basal cell carcinoma (BCC) is the most common cancer in humans, accounting for approximately 80% of non-melanoma skin cancers (NMSCs) and representing more cases annually than all other cancers combined. Over 3 million BCC cases are diagnosed in the United States annually, with the global age-standardized incidence rising by approximately 2-3% per year largely attributable to increasing UV exposure, aging populations, and improved detection. BCC arises from basal cells — the undifferentiated proliferative cells occupying the deepest layer (stratum basale) of the epidermis — through cumulative UV-induced mutation of the Hedgehog signaling pathway, predominantly PTCH1 (patched 1 tumor suppressor gene). Unlike most cancers, BCC grows slowly, very rarely metastasizes (less than 0.5% of primary BCCs), and has a mortality rate below 0.1%; it is, however, locally invasive and, if neglected, can cause progressive tissue destruction, perineural spread, and bone erosion, causing significant morbidity and disfigurement. BCC predominantly affects sun-exposed skin — over 80% arise on the head, neck, and face (particularly nose, nasolabial fold, periorbital area, and ears). Risk is highest in fair-skinned individuals of European ancestry (Fitzpatrick skin types I-II); it is rare in individuals with darker skin phototypes. The 5-year cure rate for early BCC exceeds 95% with appropriate treatment; however, local recurrence rates are significant without adequate margin assessment, and patients with one BCC have a 50% cumulative risk of developing a second primary BCC within 5 years.

Cumulative ultraviolet radiation (UVR) exposure is the dominant causative factor, responsible for the vast majority of sporadic BCCs via UV-induced somatic mutations in the Hedgehog (Hh) signaling pathway. UVB (290-320 nm) causes characteristic C→T and CC→TT pyrimidine tandem transitions in the PTCH1 (patched-1, chromosome 9q22.32) and SMO (smoothened) genes — these mutations are the molecular hallmark of UV-induced BCC. PTCH1 normally represses SMO, preventing downstream Hh pathway activation; PTCH1 loss releases SMO inhibition, enabling constitutive activation of GLI1/GLI2 transcription factors driving BCC proliferation. Key UV sources: cumulative lifetime sunlight exposure (childhood sun exposure accounts for approximately 80% of lifetime sun damage); intermittent intense sun exposure with sunburn is particularly carcinogenic; indoor tanning beds (UV-A and UV-B) increase BCC risk by up to 75% compared to non-users — the risk is highest with use before age 35. Fitzpatrick skin phototype I-II (very fair, freckles, burns always, never tans; or fair, usually burns, minimal tan): highest absolute BCC risk; blue or green eyes and red or blonde hair are independently associated. Immunosuppression: solid organ transplant recipients on calcineurin inhibitors (cyclosporin) or azathioprine have 10-16 fold elevated BCC risk; HIV-positive individuals with low CD4 counts are also at increased risk from impaired immune surveillance of UV-induced mutations. Prior therapeutic irradiation: ionizing radiation (for any cancer) in the skin field creates a permanent elevated BCC risk; latency period typically 5-20 years. Arsenic exposure (contaminated groundwater, occupational): chronic inorganic arsenic ingestion causes truncal BCCs, Bowen's disease, and arsenical keratoses. Gorlin syndrome (nevoid BCC syndrome, PTCH1 germline mutation, autosomal dominant): characterized by hundreds to thousands of BCCs beginning in the second decade, odontogenic keratocysts of the jaw, calcification of the falx cerebri, skeletal anomalies, and predisposition to medulloblastoma; aggressive surveillance with vismodegib chemoprevention indicated.

BCC presents as several distinct clinical subtypes with characteristic morphology, predominantly affecting sun-exposed areas (face, ears, scalp, neck, upper trunk). Nodular BCC (most common, approximately 60%): pearly or translucent flesh-colored or pink papule or dome-shaped nodule with a rolled (heaped) border, often with arborizing telangiectasias visible at the surface; may develop central ulceration with a crusted center (rodent ulcer) — the classic presentation of neglected nodular BCC; the rolled border and telangiectasias are characteristic and distinguish BCC from a simple scar or cyst. Superficial BCC (approximately 15-25%): flat, thin, pink or red scaly or eczematous plaque with a subtle rolled border — most common on the trunk and extremities; may be clinically misdiagnosed as eczema, psoriasis, tinea, or Bowen's disease; slowly expands centrifugally over years. Morpheaform (sclerosing) BCC (approximately 5-10%): the most clinically aggressive subtype — presents as an indurated, firm, white or yellow waxy scar-like plaque with ill-defined margins blending imperceptibly into surrounding normal skin; lacks the characteristic rolled border or telangiectasias of nodular BCC; frequently underestimated in extent clinically, with histological margins extending several centimetres beyond visible borders. Infiltrative BCC: similar to morpheaform but less sclerotic stroma; also has poorly defined clinical margins and carries high recurrence risk. Pigmented BCC: brown, blue-gray, or black pigmentation from melanin within a nodular or superficial BCC — may clinically mimic melanoma or a pigmented seborrhoeic keratosis; dermoscopy distinguishes from melanoma by arborizing vessels and absence of irregular pigment network. Basosquamous BCC: aggressive mixed basal and squamous differentiation; higher metastatic potential than pure BCC. All BCC subtypes: characteristically slow-growing, typically asymptomatic in early stages (no pain, itching, or bleeding until erosion develops), and may remain stable for months before rapid local growth. Perineural invasion (more common in morpheaform): produces paresthesia, pain, or facial numbness/weakness in advanced cases.

Clinical examination is the starting point — experienced clinicians recognize BCC with approximately 80-90% clinical accuracy for typical lesions. Dermoscopy (dermatoscopy): non-invasive polarized light magnification significantly improves diagnostic accuracy for distinguishing BCC from sebaceous hyperplasia, intradermal nevi, melanoma, and other skin tumors. BCC-specific dermoscopic features: arborizing (tree-like, large calibre) vessels that branch from a central vessel; blue-grey ovoid nests (well-circumscribed ovoid structures of homogeneous blue-grey color); spoke-wheel structures (brown or grey radial projections); leaf-like areas (brown or grey discrete peripheral streaks); multiple small erosions (absent in benign lesions); shiny white areas; blue-grey dots. Biopsy: definitive diagnosis requires histopathological tissue examination — punch biopsy (3-4 mm punch for medium-sized lesions, providing a tissue core including epidermis and dermis), shave biopsy (for superficial lesions), or incisional biopsy. Histological classification: nodular, superficial, micronodular, infiltrative, morpheaform, basosquamous, fibroepithelioma of Pinkus — critical for surgical margin planning, as aggressive subtypes require wider excision margins. MRI face/head: indicated for large, deeply invasive, or recurrent BCCs to assess perineural invasion (particularly along the facial nerve V1, V2, V3 divisions) and bone erosion — perineural BCC requires extended surgical resection with nerve sacrifice and adjuvant radiotherapy. Staging: NCCN low-risk and high-risk stratification guides treatment selection — high-risk features include: aggressive histological subtype, location H zone (central face, ears, eyelids, lips, nose), size above 20 mm, poorly defined borders, recurrent BCC, perineural or vascular invasion, and immunosuppression. Formal AJCC 8th edition TNM staging is applied only for locally advanced (T3-T4) or rare metastatic BCC.

Treatment selection depends on BCC histological subtype, size, location, risk category (NCCN low-risk vs high-risk), patient age, comorbidities, and patient preference. Mohs micrographic surgery (MMS): the gold-standard procedure for high-risk BCC — sequential horizontal excision of tissue layers with immediate frozen section histopathological margin assessment of 100% of peripheral and deep margins; the surgeon removes additional tissue only where positive margins persist; final cure rates exceeding 99% for primary BCC and 95% for recurrent BCC; preferred for H-zone facial BCCs (periorbital, perinasal, perioral, preauricular, postauricular), large BCCs above 20 mm, aggressive subtypes (morpheaform, infiltrative, micronodular, basosquamous), recurrent BCCs, and BCCs with perineural invasion. Standard surgical excision: appropriate for low-risk BCC with clinically defined margins — recommended surgical margins: 4 mm for low-risk nodular/superficial BCC below 20 mm (achieves >90% cure rate); 5-10 mm for high-risk BCCs at non-critical sites. Curettage and electrodesiccation (ED&C): curettage (curette to scrape tumor, taking advantage of the soft consistency of BCC versus surrounding dermis) followed by electrodesiccation; appropriate for small (below 1 cm), primary, nodular BCCs at low-risk sites; not appropriate for morpheaform, infiltrative, or scalp/hair-bearing sites. Cryotherapy (liquid nitrogen): for small, primary, superficial BCCs in non-critical locations in patients who are poor surgical candidates. Radiotherapy (external beam): effective primary treatment for inoperable patients or when surgery would cause unacceptable functional/cosmetic deficit; fractionated RT achieves cure rates of approximately 90-95%; also used as adjuvant after Mohs for perineural invasion; not recommended in younger patients given long-term skin effects and low secondary malignancy risk. Topical therapies (for superficial BCC only): imiquimod 5% cream (aldara — immune response modifier, applies 5 days/week for 6 weeks, complete response rate approximately 80%); 5-fluorouracil (Efudix 5% cream twice daily for 3-6 weeks, complete response approximately 70-80%). Photodynamic therapy (PDT): for superficial and thin nodular BCC. Hedgehog pathway inhibitors for locally advanced or metastatic BCC: vismodegib (Erivedge, SMO inhibitor) 150 mg orally once daily — ERIVANCE trial: ORR 60% locally advanced, 30% metastatic; sonidegib (Odomzo) 200 mg orally once daily — BOLT trial: ORR 58% locally advanced; response is often durable but approximately 20-30% develop resistance from SMO mutations or pathway bypass.

Basal cell carcinoma carries an excellent prognosis overall — it is one of the most treatable cancers when managed appropriately. The 5-year cure rate for primary BCC treated with surgery (Mohs or standard excision) exceeds 95% for most subtypes and locations. Mohs micrographic surgery achieves cure rates exceeding 99% for primary BCC and approximately 95% for recurrent BCC, making it the most effective treatment for high-risk disease. Metastatic BCC is exceedingly rare (fewer than 0.5% of cases), but when it occurs, carries a poor prognosis — median survival of approximately 10-20 months even with hedgehog pathway inhibitors (vismodegib or sonidegib). Without treatment, BCC grows locally and infiltrates deeper structures including cartilage, bone, and nerves, causing significant functional and cosmetic morbidity — particularly around the eyes, ears, and nose. Local recurrence without metastasis carries a good prognosis when managed with repeat Mohs surgery or excision. The main prognostic concern for BCC is local recurrence and the development of new primary BCCs — patients with one BCC have approximately 50% cumulative risk of developing a second primary BCC within 5 years and up to 44% risk of developing any new skin cancer within 3 years. Adverse prognostic features indicating higher recurrence risk include: morpheaform or infiltrative histological subtype, perineural invasion, positive surgical margins, location in the H zone of the face (periocular, perinasal, perioral, preauricular), immunosuppression from organ transplantation or systemic disease, and prior treatment failure. Gorlin syndrome (nevoid BCC syndrome) patients require intensive lifelong dermatological surveillance due to continuous new BCC development from birth onwards. BCC does not reduce overall life expectancy in the vast majority of patients when adequately managed, making primary prevention and early treatment highly impactful.

UV protection is the cornerstone of BCC prevention, reducing the risk substantially. Apply broad-spectrum SPF 30+ sunscreen (preferably SPF 50+) daily to all sun-exposed skin, reapplying every 2 hours during outdoor activity. Wear sun-protective clothing, wide-brimmed hats, and UV-blocking sunglasses. Completely avoid indoor tanning beds, which increase BCC risk by up to 75%. Seek shade during peak UV hours (10am-4pm). Individuals with prior BCC, Gorlin syndrome, organ transplantation (immunosuppression dramatically elevates risk), or significant cumulative sun exposure benefit from annual full-body skin examinations by a dermatologist. Nicotinamide (vitamin B3, 500 mg twice daily) has shown modest reduction in new BCC in high-risk individuals in the ONTRAC trial.

Any new skin lesion with a pearly or translucent quality, rolled borders, or visible blood vessels on the face, ears, scalp, or neck should be evaluated by a dermatologist. A skin sore that does not heal within 4-6 weeks, repeatedly bleeds or crusts, or appears as a scar without prior injury warrants prompt assessment. Individuals with a personal history of BCC should undergo regular skin surveillance — approximately 50% will develop another BCC within 5 years. Fair-skinned individuals with significant lifetime sun exposure or tanning bed use, those with organ transplants, and individuals with Gorlin syndrome should have annual dermatological examinations even without active symptoms. Changes in an existing lesion — growth, colour change, new bleeding, or irregular borders — require same-week evaluation.